Patient Advisory Board for Chronic Rhinosinusitis - A EUFOREA initiative.


Journal

Rhinology
ISSN: 0300-0729
Titre abrégé: Rhinology
Pays: Netherlands
ID NLM: 0347242

Informations de publication

Date de publication:
01 Oct 2019
Historique:
pubmed: 10 4 2019
medline: 14 11 2019
entrez: 10 4 2019
Statut: ppublish

Résumé

Despite the high prevalence of chronic rhinosinusitis (CRS) and its impact on patients' quality of life, no European patient organization that advocates for patients with CRS currently exists. To fill this gap and give a voice to CRS patients, EUFOREA has created a patient advisory board, whose goal is to better understand the real-life needs of patients, to raise awareness at political level and to involve patients in the development of novel integrated solutions to accelerate access to accurate diagnosis and treatments. This report summarizes the key discussion points from the kick-off meeting of the board on the 8th June 2018 and provides an outline of the key objectives for the future.

Identifiants

pubmed: 30963145
pii: 1887
doi: 10.4193/Rhin19.012
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

331-335

Auteurs

B Pugin (B)

European Forum for Research and Education in Allergy and Airway diseases (EUFOREA), Brussels, Belgium; Allergy and Clinical Immunology Research Group, Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium.

L Deneyer (L)

European Forum for Research and Education in Allergy and Airway diseases (EUFOREA), Brussels, Belgium.

C Bachert (C)

The Upper Airways Research Laboratory, Department of Oto-Rhino-Laryngology, Ghent University Hospital, Ghent, Belgium; Division of ENT Diseases, Clintec, Karolinska Institute, Stockholm, Sweden.

I Alobid (I)

IDIBAPS, Hospital ClÃ-nic, Universitat de Barcelona, CIBERES, Barcelona, Catalonia, Spain.

J Bousquet (J)

Department of Respiratory Disease, University Hospital Arnaud de Villeneuve, Montpellier, France.

G De Carlo (G)

The European Federation of Allergy and Airways Diseases patients associations (EFA), Brussels, Belgium.

W J Fokkens (WJ)

Department of Otorhinolaryngology, Academic Medical Centre, Amsterdam, The Netherlands.

S Gane (S)

Department of Otolaryngology, Royal National Throat Nose and Ear Hospital, London, UK.

C Hopkins (C)

ENT Department, Guy’s and St Thomas’ NHS Foundation Trust, London, UK.

C Holzmeister (C)

Department of Otorhinolaryngology, Medical University of Graz, Graz, Austria.

C Langdon (C)

IDIBAPS, Hospital ClÃ-nic, Universitat de Barcelona, CIBERES. Barcelona, Catalonia, Spain.

E S Lourijsen (ES)

Department of Otorhinolaryngology, Academic Medical Centre, Amsterdam, The Netherlands.

V J Lund (VJ)

Department of Otolaryngology, Royal National Throat Nose and Ear Hospital, London, UK.

G Marien (G)

European Forum for Research and Education in Allergy and Airway diseases (EUFOREA), Brussels, Belgium.

M Mavris (M)

European Medicines Agency (EMA), London, UK.

J Mullol (J)

IDIBAPS, Hospital ClÃ-nic, Universitat de Barcelona, CIBERES, Barcelona, Catalonia, Spain.

C Pereira-Perez (C)

IDIBAPS, Hospital ClÃ-nic, Universitat de Barcelona, CIBERES, Barcelona, Catalonia, Spain.

P V Tomazic (PV)

Department of Otorhinolaryngology, Medical University of Graz, Graz, Austria.

O Vanderveken (O)

ENT Department, University Hospital of Antwerp, Wilrijk, Belgium.

P W Hellings (PW)

Allergy and Clinical Immunology Research Group, Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium; Department of Otorhinolaryngology, Academic Medical Centre, Amsterdam, The Netherlands; Clinical Department of Otorhin.

S F Seys (SF)

European Forum for Research and Education in Allergy and Airway diseases (EUFOREA), Brussels, Belgium; Allergy and Clinical Immunology Research Group, Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH